Results 11 to 20 of about 2,262 (198)
PLoS ONE, 2019 AimsDrug-induced liver damage characterized by serum alanine aminotransferase (ALT) elevation often occurs in direct-acting antiviral (DAA) combination therapy for chronic hepatitis C virus (HCV) infection.
Keizo Kato +7 more
doaj +4 more sources
Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients [PDF]
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2018 Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
D. T. Abdurakhmanov +4 more
doaj +3 more sources
Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C [PDF]
Biomedicines, 2021 The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated.
Satoshi Takakusagi +7 more
doaj +3 more sources
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions [PDF]
Journal of the Formosan Medical Association, 2019 Background/Purpose: Treatment with daclatasvir plus asunaprevir (DCV + ASV) for 24 weeks provided a sustained virologic response (SVR) rate of over 90% in hepatitis C virus genotype 1b (HCV-1b) infected patients without non-structural 5A (NS5A ...
Ming-Lung Yu +16 more
doaj +3 more sources
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
Gut and Liver, 2018 Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki +11 more
doaj +2 more sources
Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir [PDF]
, 2019 The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9),microRNA (miR)122 and low‑density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b ...
Tatsuki Ichikawa +15 more
openalex +3 more sources
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection [PDF]
Therapeutics and Clinical Risk Management, 2014 Ivan Gentile,1 Antonio Riccardo Buonomo,1 Emanuela Zappulo,1 Giuseppina Minei,1 Filomena Morisco,2 Francesco Borrelli,1 Nicola Coppola,3 Guglielmo Borgia1 1Section of Infectious Diseases, 2Section of Gastroenterology, Department of Clinical Medicine and ...
Gentile I +7 more
doaj +3 more sources
Annals of Hepatology, 2017 Background: The efficacy and safety of asunaprevir + daclatasvir combination therapy for treatment of hepatitis C virus (HCV) in compensated cirrhotic patients was not fully evaluated in real-world.
Akihiro Tamori +12 more
doaj +2 more sources
Gut and Liver, 2019 Background/Aims We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. Methods : We performed a single-arm, multicenter prospective study.
Byung Seok Lee +11 more
doaj +2 more sources